Insmed Inc (INSM)vsTelix Pharmaceuticals Limited (TLX)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
TLX
Telix Pharmaceuticals Limited
$8.90
+1.48%
HEALTHCARE · Cap: $3.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Telix Pharmaceuticals Limited generates 10% more annual revenue ($664.23M vs $606.42M). TLX leads profitability with a 1.6% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
TLX
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INSM.
Margin of Safety
-4850.0%
Fair Value
$0.14
Current Price
$8.90
$8.76 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Revenue surging 58.9% year-over-year
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Distress zone — elevated risk
ROE of 3.1% — below average capital efficiency
1.6% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : TLX
The strongest argument for TLX centers on Revenue Growth. Revenue growth of 58.9% demonstrates continued momentum.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : TLX
The primary concerns for TLX are EPS Growth, Altman Z-Score, Return on Equity. A P/E of 475.5x leaves little room for execution misses. Thin 1.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while TLX is a hypergrowth play — different risk/reward profiles.
TLX carries more volatility with a beta of 1.22 — expect wider price swings.
TLX is growing revenue faster at 58.9% — sustainability is the question.
TLX generates stronger free cash flow (-93M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 32/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Telix Pharmaceuticals Limited
HEALTHCARE · BIOTECHNOLOGY · USA
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company is headquartered in North Melbourne, Australia.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?